Story perspectives

Data Safety Board Backs Dose Escalation for ER-100

By Drooid · Oct 9, 2026, 6:45 PM UTC · How we work

Summary

Life Biosciences Escalates Dose

Life Biosciences reported ER-100 was well-tolerated through Day 56 in three open-angle glaucoma participants.
Two participants showed preliminary visual-field improvements during the 56-day assessment.
The Data Safety Monitoring Board recommended escalating to Dose Level 2, said CSO Sharon Rosenzweig-Lipson, Ph.D.
The trial used a single intravitreal injection of Dose Level 1 (2×10¹¹ vg) plus daily oral doxycycline.
An oral prednisolone taper was given to reduce inflammation from the AAV-2 immune response.

Summary

New Limit Secures Funding

New Limit secured $435 million Series C from Peter Thiel’s Founders Fund for liver-cell reprogramming trials in 2027.
Life Biosciences’ COO Michael Ringel reported animal successes in arthritis, hypertension, fatty liver and Alzheimer’s, suggesting broader scope.
Altos Labs, backed by Jeff Bezos, hired Joan Mannick to lead product development for human longevity trials.
Retro Biosciences, backed by Sam Altman, is pursuing cellular reprogramming, intensifying the Silicon Valley race.

1 of 2

Life Biosciences Escalates Dose

Life Biosciences reported ER-100 was well-tolerated through Day 56 in three open-angle glaucoma participants.
Two participants showed preliminary visual-field improvements during the 56-day assessment.
The Data Safety Monitoring Board recommended escalating to Dose Level 2, said CSO Sharon Rosenzweig-Lipson, Ph.D.
The trial used a single intravitreal injection of Dose Level 1 (2×10¹¹ vg) plus daily oral doxycycline.
An oral prednisolone taper was given to reduce inflammation from the AAV-2 immune response.

1 / 2